Ricerca Biosciences has been granted a Drug Enforcement Administration (DEA) license. The DEA license allows the company to handle multiple kilos of controlled Schedule II-V substances for R&D projects at its Concord, OH facility, including preparation of Phase I to Phase II clinical bulk API supplies.

DEA licenses companies based on documented accountability of material usage and disposal, secure storage and strong ICH Q7A compliance, as well as a team of experienced chemists to execute the complex synthetic routes.

“We have the ability to move forward on clients’ R&D projects that require a DEA license with no delay,” said Rich Donaldson, Ph.D., vice president of chemical development at Ricerca. “We are proud of our track record and dedication to excellence supporting this license, and more importantly, the license signifies our commitment to rapidly moving projects forward.”


Click here to learn more about Ricerca